Mesenchymal stem cell treatment improves outcome of COVID-19 patients via multiple immunomodulatory mechanisms

The infusion of coronavirus disease 2019 (COVID-19) patients with mesenchymal stem cells (MSCs) potentially improves clinical symptoms, but the underlying mechanism remains unclear. We conducted a randomized, single-blind, placebo-controlled (29 patients/group) phase II clinical trial to validate pr...

Full description

Saved in:
Bibliographic Details
Published inCell research Vol. 31; no. 12; pp. 1244 - 1262
Main Authors Zhu, Rongjia, Yan, Tingdong, Feng, Yingmei, Liu, Yan, Cao, Hongcui, Peng, Gongxin, Yang, Yanlei, Xu, Zhen, Liu, Jingqi, Hou, Wei, Wang, Xiaoyue, Li, Zhe, Deng, Luchan, Wang, Shihua, Li, Jing, Han, Qin, Li, Hongling, Shan, Guangliang, Cao, Yinghao, An, Xingyan, Yan, Jianshe, Zhang, Zhonghui, Li, Huafei, Qu, Xuebin, Zhu, Jiaqi, Zhou, Shumin, Wang, Jiao, Zhang, Fengchun, Gao, Jinming, Jin, Ronghua, Xu, Dayong, Ma, Yan-Qing, Huang, Tao, Peng, Shuang, Zheng, Zhi, Stambler, Ilia, Gilson, Eric, Lim, Lee Wei, Moskalev, Alexey, Cano, Antonio, Chakrabarti, Sasanka, Ulfhake, Brun, Su, Huanxing, Xu, Haoying, Xu, Sihuan, Wei, Feng, Brown-Borg, Holly M., Min, Kyung-Jin, Ellison-Hughes, Georgina, Caruso, Calogero, Jin, Kunlin, Zhao, Robert Chunhua
Format Journal Article
LanguageEnglish
Published Singapore Springer Singapore 01.12.2021
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…